Samuel Singer

Samuel Singer

Auto-generated profile, based on publicly available information

Samuel Singer

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2010 in Nature
Verified
Journal Article
Open access
PDF file
RBRameen Beroukhim
Rameen Beroukhim
CMCraig H. Mermel
Craig H. Mermel
DPDale Porter
Dale Porter
GWGuo Wei
Guo Wei
SRSoumya Raychaudhuri
Soumya Raychaudhuri
MMMatthew Meyerson
Matthew Meyerson
A powerful way to discover key genes with causal roles in oncogenesis is to identify genomic regions that undergo frequent alteration in human cancers. Here we present high-resolution analyses of somatic copy-number alterations (SCNAs) from 3,131 cancer specimens, belonging largely to 26 histological types. We identify 158 regions of focal SCNA that are altered at significant frequency across several cancer types, of which 122 cannot be explained by the presence of a known cancer target gene located within these regions. Several gene families are enriched among these regions of focal SCNA, including the BCL2 family of apoptosis regulators and the NF-κΒ pathway. We show that cancer cells containing amplifications surrounding the MCL1 and BCL2L1 anti-apoptotic genes depend on the expression of these genes for survival. Finally, we demonstrate that a large majority of SCNAs identified in individual cancer types are present in several cancer types.

15 August 2002 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GDGeorge D. Demetri
George D. Demetri
MMMargaret von Mehren
Margaret von Mehren
CBCharles D. Blanke
Charles D. Blanke
AAAnnick D. Van Den Abbeele
Annick D. Van Den Abbeele
BEBurton Eisenberg
Burton Eisenberg
HJHeikki Joensuu
Heikki Joensuu
Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors. We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor. We assessed antitumor response and the safety and tolerability of the drug. Pharmacokinetics were assessed in a subgroup of patients. A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily. Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for technical reasons, response could not be evaluated in 7 patients (4.8 percent). No patient had a complete response to the treatment. The median duration of response had not been reached after a median follow-up of 24 weeks after the onset of response. Early resistance to imatinib was noted in 20 patients (13.6 percent). Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common. Gastrointestinal or intraabdominal hemorrhage occurred in approximately 5 percent of patients. There were no significant differences in toxic effects or response between the two doses. Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia. Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.

1 December 2003 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MHMichael C. Heinrich
Michael C. Heinrich
CCChristopher L. Corless
Christopher L. Corless
GDGeorge D. Demetri
George D. Demetri
CBCharles D. Blanke
Charles D. Blanke
MMMargaret von Mehren
Margaret von Mehren
JFJonathan A. Fletcher
Jonathan A. Fletcher
Purpose: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate. The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST. Patients and Methods: GISTs from 127 patients enrolled onto a phase II clinical study of imatinib were examined for mutations of KIT or PDGFRA. Mutation types were correlated with clinical outcome. Results: Activating mutations of KIT or PDGFRA were found in 112 (88.2%) and six (4.7%) GISTs, respectively. Most KIT mutations involved exon 9 (n = 23) or exon 11 (n = 85). All KIT mutant isoforms, but only a subset of PDGFRA mutant isoforms, were sensitive to imatinib, in vitro. In patients with GISTs harboring exon 11 KIT mutations, the partial response rate (PR) was 83.5%, whereas patients with tumors containing an exon 9 KIT mutation or no detectable mutation of KIT or PDGFRA had PR rates of 47.8% (P = .0006) and 0.0% (P < .0001), respectively. Patients whose tumors contained exon 11 KIT mutations had a longer event-free and overall survival than those whose tumors expressed either exon 9 KIT mutations or had no detectable kinase mutation. Conclusion: Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clinical response to imatinib. PDGFRA mutations can explain response and sensitivity to imatinib in some GISTs lacking KIT mutations.

1 November 2017 in Cell
Verified
Journal Article
Open access
AAAdam Abeshouse
Adam Abeshouse
CAClement Adebamowo
Clement Adebamowo
SASally N. Adebamowo
Sally N. Adebamowo
RARehan Akbani
Rehan Akbani
TATeniola Akeredolu
Teniola Akeredolu
EZErik Zmuda
Erik Zmuda
Sarcomas are a broad family of mesenchymal malignancies exhibiting remarkable histologic diversity. We describe the multi-platform molecular landscape of 206 adult soft tissue sarcomas representing 6 major types. Along with novel insights into the biology of individual sarcoma types, we report three overarching findings: (1) unlike most epithelial malignancies, these sarcomas (excepting synovial sarcoma) are characterized predominantly by copy-number changes, with low mutational loads and only a few genes (TP53, ATRX, RB1) highly recurrently mutated across sarcoma types; (2) within sarcoma types, genomic and regulomic diversity of driver pathways defines molecular subtypes associated with patient outcome; and (3) the immune microenvironment, inferred from DNA methylation and mRNA profiles, associates with outcome and may inform clinical trials of immune checkpoint inhibitors. Overall, this large-scale analysis reveals previously unappreciated sarcoma-type-specific changes in copy number, methylation, RNA, and protein, providing insights into refining sarcoma therapy and relationships to other cancer types.

1 September 1998 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PSPasha Sarraf
Pasha Sarraf
EMElisabetta Mueller
Elisabetta Mueller
DJDaniel Jones
Daniel Jones
FKFrederick J. King
Frederick J. King
DDDaniel J. DeAngelo
Daniel J. DeAngelo
BSBruce M. Spiegelman
Bruce M. Spiegelman

13 January 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DRDan R Robinson
Dan R Robinson
YWYi-Mi Wu
Yi-Mi Wu
SKShanker Kalyana-Sundaram
Shanker Kalyana-Sundaram
XCXuhong Cao
Xuhong Cao
RLRobert J Lonigro
Robert J Lonigro
ACArul M Chinnaiyan
Arul M Chinnaiyan